# Lyra Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lyra-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.lyratherapeutics.com
- Total disclosed funding: $125M
- Latest round: Series C (Jan 10, 2020)
- Investors on record: 10

## About

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for patients with unmet medical needs, particularly in ear, nose, and throat conditions.Founded in 2018, Lyra Therapeutics, Inc. operates as a biotechnology firm specializing in therapeutics for ear, nose, and throat disorders. The company is headquartered in Watertown, US. Maria Palasis is the CEO. Lyra has raised a total of USD 100.50 mn, including a Private Placement/Follow on round of USD 100.50 mn in April 2022. The firm has engaged in 12 deals to date, with its most recent investment occurring on April 13, 2022.Lyra Therapeutics, Inc. develops therapies aimed at treating various ENT conditions, leveraging advanced drug delivery technologies. Their product pipeline includes therapies designed for chronic rhinosinusitis and other nasal conditions, addressing the needs of patients through innovative drug delivery systems that ensure sustained medication release.In 2024, Lyra Therapeutics, Inc. reported a revenue of USD 1.53 mn with an EBITDA of USD -95.88 mn.Lyra Therapeutics, Inc. plans to expand its product offerings, focusing on additional therapies targeting chronic nasal conditions with anticipated launches in the near future. The company aims to penetrate new geographical markets, particularly in Europe and Asia, by 2025. Recent funding from the Private Placement will be allocated to advancing clinical trials and scaling production capabilities for its innovative therapies.

## Funding rounds

- Series C, Jan 10, 2020, $30M — Intersouth Partners, North Bridge Venture Partners, Polaris Partners, ArrowMark Partners, RA Capital Management, Perceptive Advisors, Soleus Capital, Clifton Capital
- Series B, Sep 26, 2018, $30M — Intersouth Partners, North Bridge Venture Partners, Polaris Partners, ArrowMark Partners, RA Capital Management, Perceptive Advisors, Soleus Capital
- Series C, Apr 12, 2013, $18M — Intersouth Partners, Polaris Partners
- Series B, Sep 8, 2011, $12M — Essex Woodlands, Intersouth Partners, North Bridge Venture Partners, Polaris Partners
- Series C, May 12, 2010, $10M — Intersouth Partners, North Bridge Venture Partners, Polaris Partners, Broadview Ventures
- Series C, Apr 3, 2009, $12M — Essex Woodlands, Intersouth Partners, North Bridge Venture Partners, Polaris Partners
- Series B, Nov 30, 2007, $0.1M — Intersouth Partners, North Bridge Venture Partners, Polaris Partners
- Series B, Sep 18, 2007, $13M — Intersouth Partners, North Bridge Venture Partners, Polaris Partners

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series B, Series C
- North Bridge Venture Partners (https://capitalatlas.ai/funds/north-bridge-venture-partners) — Series B, Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B, Series C
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series C, Series B
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series C
- ArrowMark Partners — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B, Series C
- Clifton Capital — Series C